GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (FRA:20B) » Definitions » Asset Turnover

Biomark Diagnostics (FRA:20B) Asset Turnover : 0.04 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Biomark Diagnostics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Biomark Diagnostics's Revenue for the three months ended in Dec. 2023 was €0.03 Mil. Biomark Diagnostics's Total Assets for the quarter that ended in Dec. 2023 was €0.68 Mil. Therefore, Biomark Diagnostics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.04.

Asset Turnover is linked to ROE % through Du Pont Formula. Biomark Diagnostics's annualized ROE % for the quarter that ended in Dec. 2023 was 188.31%. It is also linked to ROA % through Du Pont Formula. Biomark Diagnostics's annualized ROA % for the quarter that ended in Dec. 2023 was -163.53%.


Biomark Diagnostics Asset Turnover Historical Data

The historical data trend for Biomark Diagnostics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics Asset Turnover Chart

Biomark Diagnostics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.78 - 0.04 0.13

Biomark Diagnostics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.05 0.06 0.06 0.04

Competitive Comparison of Biomark Diagnostics's Asset Turnover

For the Diagnostics & Research subindustry, Biomark Diagnostics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomark Diagnostics's Asset Turnover Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Biomark Diagnostics's Asset Turnover falls into.



Biomark Diagnostics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Biomark Diagnostics's Asset Turnover for the fiscal year that ended in Mar. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Mar. 2023 )/( (Total Assets (A: Mar. 2022 )+Total Assets (A: Mar. 2023 ))/ count )
=0.104/( (1.056+0.5)/ 2 )
=0.104/0.778
=0.13

Biomark Diagnostics's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0.029/( (0.438+0.922)/ 2 )
=0.029/0.68
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Biomark Diagnostics  (FRA:20B) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Biomark Diagnostics's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-1.112/-0.5905
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-1.112 / 0.116)*(0.116 / 0.68)*(0.68/ -0.5905)
=Net Margin %*Asset Turnover*Equity Multiplier
=-958.62 %*0.1706*-1.1516
=ROA %*Equity Multiplier
=-163.53 %*-1.1516
=188.31 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Biomark Diagnostics's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-1.112/0.68
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-1.112 / 0.116)*(0.116 / 0.68)
=Net Margin %*Asset Turnover
=-958.62 %*0.1706
=-163.53 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Biomark Diagnostics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Biomark Diagnostics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomark Diagnostics (FRA:20B) Business Description

Traded in Other Exchanges
Address
130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early treatment for cancer. Its research and development are focused on the role that metabolomics plays in early cancer detection. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.

Biomark Diagnostics (FRA:20B) Headlines

No Headlines